A Study to Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Cancer Non Hodgkin Lymphoma (NHL) Diffuse Large B-Cell Lymphoma (DLBCL) Lymphoma
For the latest version of this information please go to www.forpatients.roche.com